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EVSI Expected value of sample information 
EUC Electrolytes, urea and creatinine 
FBC Full blood count 
FDA United States Food and Drug Administration 
FISH Fluorescence in situ hybridization 
GP General practitioner 
HBOT Hyperbaric oxygen therapy 




HR Hazard rate 
HRR Hazard rate ratio 
HRS Hazard Rate of Progression Following Stable Disease 
HRP Hazard rate of overall progression 
HTA Health technology assessment 
ICER Incremental cost-effectiveness ratio 
ICSP Intravenous Chemotherapy Supply Program 
IHC Immunohistochemistry 
iPAH Idiopathic pulmonary arterial hypertension 
IPCW Inverse Probability of Censoring Weights 
ISH In situ hybridisation 
ISPOR International Society for Pharmacoeconomics and Outcomes Research 
ITT Intent to treat 
IV Intravenous 
kg Kilograms 
LFT Liver function test 
ln Natural logarithm 
LVEF Left ventricular ejection fraction 
LYG Life years gained 
MAUI Multi-attribute utility instrument 
MBC Metastatic breast cancer 
MBS Medical Benefits Scheme 
MES Managed Entry Scheme 
mg Milligrams 
MUGA Multi gated acquisition scan 
MSAC Medical Services Advisory Committee 
n Number of patients/respondents etc 
NA Not applicable 
NHMRC National Health and Medical Research Council 
NHS CRD National health service Centre for Reviews and Dissemination 
NHS EED National health service economic evaluation database 
NHS National health service 
NICE National Institute for Health and Care Excellence 
NIP National Immunisation Programme 
NPS National Prescribing Service 
NSW New South Wales 
NR Not reported 
NT Northern Territory 
OECD Organisation for Economic Co-operation and Development 
OIR Only in research 
OR Odds ratio 
OS Overall survival 
OWR Only with research 
PBAC Pharmaceutical Benefits Advisory Committee 
PBPA Pharmaceutical Benefits Pricing Authority 
PBS Pharmaceutical Benefits Scheme 
PFLY Progression free life year 
PFS Progression free survival 
PgR Progesterone receptor 
PPS Post-Progression Survival 
PSA Probabilistic sensitivity analysis 




QALY Quality-adjusted life year 
qd Once daily 
QLD Queensland 
qw Once weekly 
q3w Once three weekly 
r Response rate 
RCT Randomised controlled clinical trial 
RPBS Repatriation Pharmaceutical Benefits Scheme 
RPSFT Rank preserving structural failure time 
RRMA Rural, remote and metropolitan areas 
RR Relative Risk 
SA South Australia 
SE Standard error 
SD Standard deviation 
SMDM Society for Medical Decision Making 
TAS Tasmania 
TGA Therapeutic Goods Administration 
TTO Time trade-off 
TTP Time to progression 
UK United Kingdom 
US United States of America 
VIC Victoria 
VOI Value of information 
WA Western Australia 






Economic evaluation is a tool used by decision makers to ensure that promising high cost drugs that 
receive public funding are value for money. Funding decisions are inevitably based on limited data 
and there is always some uncertainty regarding whether the drug be cost-effective in clinical 
practice. An incorrect funding decision will reduce society’s welfare. The aim of this thesis is to 
investigate and evaluate current and potential methods to assess and manage uncertainty regarding 
the cost-effectiveness of a drug in clinical practice. 
The thesis undertakes an in-depth case study of a specific high cost drug which captures many of 
the features common to emerging high cost drugs: trastuzumab (Herceptin) for the treatment for 
human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. 
The research had five stages: 1) a systematic review and critique of published economic evaluations 
was conducted; 2) an economic model was developed using trial evidence; 3) uncertainty was 
analysed using different methods, including value of information analysis; 4) real-world 
observational data were analysed to inform modifications to model parameters; and 5) the model 
was adjusted to estimate the cost-effectiveness in clinical practice. 
The systematic review demonstrated the importance of judgements made regarding the structure of 
the analysis and the data sources used in economic models. The cost-effectiveness of trastuzumab 
was estimated to be $180,910/Quality Adjusted Life Year (QALY) gained in 2001 (when first 
considered for PBS-subsidy). This is above the range usually considered cost-effective. The model 
was used to demonstrate how to estimate the value of collecting real-world observational data to be 
used in economic evaluations. The case study was extended by exploring a hypothetical coverage 
with evidence development (CED) arrangement based on observational data collected within the 
Australian government’s Herceptin Program. It was concluded that the hypothetical CED 
arrangement would not have been appropriate unless the cost of trastuzumab was reduced. The 
analysis of the observational data lead to policy options for achieving improved cost-effectiveness. 
In particular, non-adherence to treatment guidelines with respect to concomitant therapies and 
treatment post-progression was found. This underscores the need for post-market review. It was 
estimated that there was a net loss from funding trastuzumab via the Herceptin Program due to the 
high price of trastuzumab and non-adherence to treatment guidelines. 
This thesis demonstrates some of the challenges for decision makers regarding high cost drugs with 
limited evidence, and offers some solutions regarding how uncertainty can be managed. 
